Introduction: The Expanding Regulatory Landscape for Nitrosamine Impurities in Biologics
The nitrosamine crisis that affected the small-molecule pharmaceutical industry between 2018 and 2022, initiated by the recall of sartan antihypertensive products contaminated with NDMA and NDEA, fundamentally reshaped the global regulatory perspective on impurity control. What was initially viewed as a problem limited to chemical synthesis has since evolved into a broader manufacturing and quality concern, extending into the biologics and biotechnology sector.
Nitrosamine impurities in biologics exist within a particularly complex scientific and regulatory environment. Unlike small-molecule pharmaceuticals produced through defined chemical synthesis pathways, biologics are manufactured using living systems such as mammalian cell cultures, microbial fermentation platforms, and recombinant DNA expression technologies. Because of this, the mechanisms responsible for nitrosamine formation are less predictable, less understood, and considerably more difficult to evaluate. Nevertheless, the core toxicological concern remains unchanged. Nitrosamines continue to present significant genotoxic, mutagenic, and carcinogenic risks regardless of whether the final therapeutic product is a monoclonal antibody, therapeutic protein, recombinant vaccine, oligonucleotide, or nucleic acid-based therapy.
This article is intended for regulatory affairs professionals, analytical scientists, and QA/QC specialists working within the biologics and biopharmaceutical industries who require an up-to-date and technically accurate understanding of current regulatory expectations, scientific considerations, and practical testing approaches related to nitrosamine impurities in biological products.
Share via:
📋 Article Summary
- ResolveMass Laboratories Inc. provides advanced nitrosamine testing, method development, and regulatory risk assessment services specifically tailored for biologics, biopharmaceuticals, and other complex biotechnology-derived products.
- Regulatory oversight for nitrosamine impurities, once focused mainly on small-molecule pharmaceuticals, is increasingly extending into the biologics and biotechnology sector. However, the scientific and compliance expectations for biologics differ significantly from traditional chemically synthesized drugs.
- Current regulatory frameworks, including ICH M7(R2) and existing FDA and EMA guidance documents, do not formally require biologics to follow the same nitrosamine assessment procedures applied to small molecules. Despite this, global health authorities are actively reviewing and expanding their expectations for biologic products.
- Potential nitrosamine formation in biotechnology manufacturing may originate from several sources, including cell culture media, fermentation ingredients, excipients, process additives, water systems, and packaging materials. The level of risk is highly dependent on the specific product, process design, and manufacturing environment.
- Detecting nitrosamines in biological products presents substantial analytical challenges due to complex protein matrices, buffer interference, and extremely low target impurity concentrations. As a result, customized LC-MS/MS and high-resolution mass spectrometry (HRMS) methods are often necessary for accurate analysis.
- A science-based, risk-focused evaluation strategy is currently considered the most practical and regulatorily defensible approach for biologics manufacturers. Instead of universal testing mandates, regulators increasingly expect detailed product-specific risk assessments supported by appropriate analytical data.
Regulatory Status: Current Positions of ICH M7, FDA, and EMA on Biologics
In summary, ICH M7(R2), the FDA’s 2021 nitrosamine guidance, and EMA nitrosamine frameworks currently exclude most biologics from mandatory nitrosamine risk assessments. However, this exemption is becoming increasingly narrow, and regulatory authorities are actively reassessing the applicability of nitrosamine controls to biological products.
ICH M7(R2): Existing Scope Limitations
ICH M7(R2), the primary international guideline governing acceptable limits for DNA-reactive and mutagenic impurities, specifically applies to chemically synthesized drug substances and products. Biological and biotechnology-derived products, including monoclonal antibodies (mAbs), recombinant proteins, antibody-drug conjugates (ADCs), oligonucleotides, cell therapies, gene therapies, and recombinant vaccines, are formally excluded from the direct scope of the guideline.
Importantly, this exclusion should not be interpreted as confirmation that biologics are entirely free from nitrosamine risk. Rather, the exclusion reflects the historical assumption that manufacturing processes involving living systems would not generate the same nitrosamine impurity patterns observed in conventional chemical synthesis. Regulatory agencies are now reevaluating that assumption as more scientific evidence becomes available.
Key Scope Positions Under ICH M7(R2)
Within Scope
- Chemically synthesized active pharmaceutical ingredients (APIs)
- Drug products containing chemically synthesized APIs
Outside Scope
- Biological and biotechnology-derived products regulated under the ICH Q5 and Q6B guideline series
Special Consideration: ADCs and Conjugated Biologics
- Antibody-drug conjugates and similar hybrid products occupy a regulatory grey area
- Small-molecule payloads and linker systems associated with ADCs may independently trigger ICH M7 obligations for those specific chemical components
FDA Position: Guidance and Evolving Regulatory Expectations
The FDA’s guidance document titled “Control of Nitrosamine Impurities in Human Drugs” primarily addresses chemically synthesized pharmaceuticals. However, the agency has increasingly acknowledged that biologics are not automatically exempt from nitrosamine-related concerns.
Several FDA communications and updates issued during 2023 and 2024 indicate expanding regulatory attention toward biological products.
Key FDA Considerations Relevant to Biologics
- Certain excipients used in both small-molecule and biological formulations, including polysorbates, polyethylene glycol (PEG)-based surfactants, and selected preservatives, may contribute to nitrosamine formation regardless of drug substance type.
- FDA recommendations requiring evaluation of packaging systems and container-closure components as potential nitrosamine sources apply universally, including to biologic drug products.
- Combination products containing biological components and medical device elements are expected to undergo nitrosamine risk evaluation associated with the device materials and packaging systems.
These communications indicate that the FDA increasingly expects biologics manufacturers to evaluate nitrosamine risk proactively, even in the absence of explicit mandatory requirements.
Regulatory Compliance Support: To prepare a robust regulatory strategy that aligns with these evolving expectations, read how to conduct a comprehensive nitrosamine risk assessment for ANDA submission to ensure your files meet strict agency standards.
EMA Approach: Stepwise Risk Assessment for Biological Products
The European Medicines Agency introduced a phased nitrosamine framework beginning in 2020, followed by multiple revisions through 2023. EMA guidance established a three-step process consisting of:
- Step 1: Risk Assessment
- Step 2: Confirmatory Testing
- Step 3: Implementation of Risk-Mitigation Changes
This framework applies broadly to all marketing authorization holders, including manufacturers of biological medicinal products.
EMA’s Position on Biologics
The EMA has clearly stated that:
- Biological active substances themselves are generally considered less likely to generate nitrosamines directly.
- Formulation processes, excipients, manufacturing equipment, and shared production environments may still introduce nitrosamine risk.
- Biological products should never be automatically categorized as “risk-free” without documented, product-specific scientific evaluation.
This position effectively places biologics within a risk-based nitrosamine assessment framework even though they remain formally outside ICH M7 scope.
ICH Q12 and Lifecycle Management Implications
One frequently overlooked aspect of nitrosamine management in biologics is the relationship with ICH Q12 lifecycle management principles.
Changes involving:
- Raw materials
- Cell culture media
- Excipients
- Process aids
- Packaging systems
- Supplier sources
may significantly alter the nitrosamine risk profile of a biological product. Such modifications can potentially trigger post-approval regulatory filing obligations even when nitrosamines were not originally identified during product development.
As a result, biologics manufacturers should integrate nitrosamine risk evaluation directly into formal change-control procedures and ongoing lifecycle management systems.
Managing Lifecycle Changes: When adjustments are required post-assessment, implementing a proactive nitrosamine reformulation strategy can help alter your product’s matrix safely without introducing new impurity risks.
Formation Pathways: How Nitrosamines Can Develop in Biotech Manufacturing
Nitrosamines may arise in biotechnology-derived products through three primary mechanisms:
- Introduction through raw materials and excipients
- Formation during manufacturing and formulation processes
- Migration from packaging and container-closure systems
1. Raw Materials and Cell Culture Media
Biologic manufacturing processes depend heavily on highly complex nutrient media used for mammalian and microbial cell culture systems such as CHO, HEK293, E. coli, and Pichia platforms.
Several media components may contribute to nitrosamine formation risk.
| Raw Material / Component | Nitrosamine Risk Vector |
|---|---|
| Amino acids and hydrolysates | Contain secondary amines capable of reacting with nitrite impurities |
| Yeast extracts | May contain low levels of volatile nitrosamines |
| Vitamins such as choline | Amine-containing compounds susceptible to nitrosation |
| Antibiotics including doxycycline and tetracyclines | Contain amine functional groups vulnerable to nitrosation |
| Recombinant insulin used in serum-free media | Protein-bound amines present low but measurable risk |
| Dimethylformamide (DMF) residues | Known precursor for NDMA formation |
An additional and often underestimated contributor is nitrite contamination within water systems. Biofilm-forming microorganisms in water-for-injection (WFI) systems and purified water loops can locally generate nitrite species, thereby creating conditions suitable for nitrosation reactions.
2. Downstream Processing and Formulation Risks
Several downstream manufacturing operations may contribute to nitrosamine generation.
Chromatographic Resins
Ion-exchange and affinity chromatography resins frequently contain amine-functionalized ligands. Under acidic conditions and in the presence of trace nitrite, these ligands may generate N-nitroso compounds capable of leaching into the product stream.
Polysorbate 20 and Polysorbate 80
Polysorbate excipients are widely used in monoclonal antibody formulations as stabilizers. Their degradation pathways may generate secondary amines and related compounds that serve as nitrosamine precursors. Regulatory agencies, particularly the EMA, have specifically highlighted polysorbate degradation products as areas requiring further investigation.
Mitigating Raw Material and Formulation Risks: Learn how optimization techniques like using a secondary amine scavenger for nitrosamine prevention can block these unwanted chemical reactions from happening during formulation.
Rubber Closures and Stoppers
Rubber container-closure systems are among the best-established nitrosamine sources in pharmaceutical manufacturing. Vulcanization accelerators including thiurams and dithiocarbamates may release nitrosamines such as NDMA, NDEA, and morpholine-derived species when exposed to aqueous biological formulations over time.
3. Process Conditions Supporting Nitrosation
Biologic manufacturing does not typically involve the high-temperature synthetic chemistry associated with traditional nitrosamine formation. However, certain process conditions may still facilitate nitrosation reactions.
Low-pH Viral Inactivation Steps
Monoclonal antibody manufacturing often includes viral inactivation holds performed at pH 3.5–3.8. When amine-containing buffers coexist with trace nitrite contaminants, these conditions may theoretically support nitrosamine generation.
Lyophilization and Spray Drying
Freeze-drying and spray-drying operations can significantly concentrate trace impurities. Even very low levels of pre-existing nitrosamines may become enriched during these processes.
Investigating Root Causes: If process conditions or raw materials trigger a contamination event, explore an actionable NDMA root cause investigation case study to see how real-world manufacturers pinpoint and resolve active nitrosamine sources.
Current Testing Approaches for Nitrosamine Impurities in Biologics
The preferred analytical strategy for detecting nitrosamines in biologics involves a tiered, risk-based methodology utilizing LC-MS/MS or high-resolution mass spectrometry (HRMS). Importantly, analytical methods must be specifically adapted for complex biological matrices.
Why Conventional Nitrosamine Methods Are Inadequate for Biologics
Analytical procedures originally developed for small-molecule pharmaceuticals cannot simply be transferred to biologic products without substantial modification.
Key Analytical Challenges
Matrix Suppression
High protein concentrations in monoclonal antibody products may suppress electrospray ionization efficiency, resulting in false-negative findings unless sample cleanup and dilution procedures are carefully optimized.
Protein Binding
Nitrosamines may associate with proteins either covalently or non-covalently, necessitating extraction procedures beyond those used for conventional small-molecule analysis.
Excipient Interference
Excipients such as polysorbates, trehalose, and sucrose may co-elute with nitrosamine analytes during reversed-phase chromatography, complicating separation and quantification.
Extremely Low Target Levels
Nitrosamine acceptable intake limits are exceptionally low. For compounds such as NDMA, allowable exposure levels may correspond to analyte concentrations near trace-detection limits in high-dose biologic formulations.
Highly Potent Applications: To successfully navigate these analytical hurdles within highly sensitive workflows, review guidelines on specialized nitrosamine testing in highly potent APIs and complex biomanufacturing matrices.
Recommended Analytical Strategy
Step 1: Preliminary Risk Assessment and Target Identification
Before laboratory testing begins, manufacturers should conduct a detailed scientific risk assessment to identify:
- Plausible nitrosamine species based on manufacturing materials and processes
- Potential formation pathways
- Expected concentration ranges
- Applicable toxicological thresholds and acceptable intake limits
This targeted strategy reduces unnecessary broad-spectrum screening and improves analytical specificity.
Calculating Process Safety: A major asset during this risk assessment stage is performing a formal nitrosamine purge factor calculation to scientifically demonstrate whether your downstream purification steps naturally clear out trace contaminants.
Step 2: Method Development and Validation
| Analytical Parameter | Recommended Approach for Biologics |
|---|---|
| Sample preparation | Protein precipitation using ACN/MeOH, SPE cleanup, or supported liquid extraction |
| Chromatography | Reversed-phase LC for semi-volatile compounds; HILIC for polar analytes |
| Detection | LC-MS/MS for targeted analysis; HRMS for screening |
| Ionization | ESI positive/negative or APCI depending on analyte characteristics |
| Internal standards | Stable isotope-labeled standards are essential |
| LOQ targets | ≤10% of acceptable intake limits |
| Calibration strategy | Matrix-matched calibration required |
Matrix-matched calibration is especially important because neat solvent calibration does not adequately compensate for biological matrix effects.
Step 3: Non-Targeted and Suspect Screening
For advanced biologic modalities such as:
- mRNA therapeutics
- AAV gene therapies
- Cell therapies
where nitrosamine risks remain poorly characterized, HRMS-based non-targeted screening offers broader analytical coverage.
This workflow generally includes:
- Full-scan MS1 acquisition
- Data-dependent MS2 fragmentation
- Spectral library comparison using databases such as mzCloud, HMDB, and NIST
- Identification of characteristic nitrosamine fragmentation patterns and mass shifts
This strategy is particularly valuable during early process development and manufacturing characterization.
Step 4: Confirmatory Testing and Quantification
Any detected nitrosamine signal should undergo rigorous confirmation procedures, including:
- Retention time matching against certified standards
- Verification of quantifier and qualifier ion ratios
- Spike recovery studies within the biological matrix
- Independent repeat testing using alternative instruments or chromatographic conditions
Target spike recovery should generally fall within 80–120%.
Routine vs. Release Criteria: Understanding when to deploy these analytical methods is critical; review the requirements regarding nitrosamine batch release testing requirement rules to establish compliant release protocols.
Container-Closure and Leachable Testing in Biologics
Rubber closure systems represent one of the most significant and actionable nitrosamine risk sources in biologic products.
Recommended testing strategies include:
- Extraction studies using simulated biologic drug product conditions
- Leachable and extractable evaluations consistent with USP <1663>, USP <1664>, ISO 10993-17, and EMA packaging guidelines
- Stability testing of final products through end-of-shelf-life conditions due to the time-dependent nature of nitrosamine migration
Validated LC-MS/MS methodologies specifically designed for biological matrices are essential for reliable leachable testing.
Evaluating Packaging Impurities: For a comprehensive breakdown on analyzing risks tied to container closures, see our expert resource on packaging leachables nitrosamine e&l testing.
Risk Assessment Framework Specific to Biologics
Nitrosamine risk assessments for biologics differ substantially from traditional ICH M7 workflows in several important ways.
| Risk Assessment Element | Small-Molecule Framework | Biologics Framework |
|---|---|---|
| Starting point | Synthetic route analysis | Raw material, excipient, and packaging evaluation |
| Applicable limits | ICH M7 acceptable intake limits | AI limits, TDI values, or bespoke TTC calculations |
| Route of exposure | Primarily oral | IV, SC, IM exposure routes |
| Regulatory framework | ICH M7 mandatory | Risk-based extension using ICH Q5 principles |
| Reassessment triggers | Post-approval changes | Supplier, media, process, or packaging changes |
Potency Classification in the Biologics Context
The FDA’s “cohort of concern” nitrosamines, including:
- NDMA
- NDEA
- NMBA
- NDIPA
- NDBA
- NMPA
- MNP
remain highly relevant to biological products because these compounds may originate from:
- Packaging systems
- Shared excipients
- Water systems
- Manufacturing environments
Their acceptable intake limits apply broadly across pharmaceutical products irrespective of whether the final therapeutic agent is a small molecule or biologic.
Setting Scientific Limits: To understand how maximum daily doses impact these threshold calculations, read our guide on acceptable intake for multiple nitrosamines to effectively manage cumulative toxicological risks.
Practical Guidance for Biologics Manufacturers
Biologics manufacturers should adopt proactive and well-documented nitrosamine control strategies.
Recommended Best Practices
- Conduct formal written nitrosamine risk assessments even when perceived risk appears minimal
- Audit packaging suppliers for nitrosamine extractable data and compound-specific certifications
- Evaluate polysorbate-containing formulations carefully due to increasing regulatory attention on degradation-related impurities
- Integrate nitrosamine review checkpoints into all change-control procedures
- Apply full ICH M7 principles to small-molecule payloads and linkers used in ADCs and conjugated biologics
- Prepare proactively for future regulatory expansion related to biologics-specific nitrosamine guidance
Conclusion: Proactive Nitrosamine Management in Biologics Is Essential
The regulatory direction is increasingly evident. Nitrosamine impurities in biologics will continue to receive heightened scrutiny as scientific understanding advances and regulators accumulate additional post-market data. Manufacturers that delay implementation of comprehensive nitrosamine risk assessment programs may ultimately face substantial compliance, analytical, and operational challenges.
The most defensible position for biologics manufacturers today is a fully documented, science-driven, product-specific nitrosamine risk assessment supported by validated analytical methods and integrated into the organization’s quality management framework.
ResolveMass Laboratories Inc. provides specialized expertise in mass spectrometry, validated analytical methods for complex biological matrices, and comprehensive regulatory support for biologics manufacturers throughout the entire product lifecycle, including early-stage development, confirmatory testing, post-approval change management, and ongoing nitrosamine risk mitigation.
Partner with Analytical Experts: If you are ready to implement a validated program for your pipeline, discover how to optimize vendor vetting by evaluating our guide on nitrosamine testing cro selection.
FAQs: Nitrosamine Impurities in Biologics
At present, ICH M7(R2) does not formally include biological or biotechnology-derived products within its regulatory scope. The guideline primarily applies to chemically synthesized drug substances and related impurities. However, regulatory agencies such as the FDA and EMA still expect biologics manufacturers to assess potential nitrosamine risks associated with excipients, packaging materials, manufacturing aids, and process equipment. For this reason, performing a detailed product-specific risk assessment is considered an important part of modern biologics quality management.
Yes, nitrosamine formation can theoretically occur during mammalian cell culture under certain conditions. Cell culture media often contain amino acids, hydrolysates, vitamins, and other amine-containing ingredients that may react with trace nitrite contaminants present in water systems or introduced through microbial activity. Although the probability of significant nitrosamine generation is considered relatively low in biologic manufacturing, the risk cannot be completely excluded. Regulatory expectations increasingly favor documented scientific evaluations of these potential formation pathways.
Nitrosamine acceptable intake (AI) limits established under ICH M7 are generally based on lifetime daily exposure assumptions for an average adult patient. However, injectable biologics may present different exposure considerations because intravenously or subcutaneously administered products bypass gastrointestinal metabolism and may result in higher systemic bioavailability. As a result, some regulatory scientists believe that route-specific adjustments to acceptable intake thresholds may eventually become necessary. This topic remains under active scientific and regulatory discussion globally.
Current industry data suggest that monoclonal antibody formulations are most likely to encounter nitrosamines originating from rubber closure systems and formulation excipients. Commonly identified compounds include NDMA, NDEA, and N-nitrosomorpholine (NMOR), particularly when rubber stoppers or polysorbate-containing formulations are involved. In some cases, dimethylamine-containing process materials or excipients may also contribute to NDMA formation. These risks have become an increasing focus of both FDA and EMA investigations.
Headspace GC-MS/MS is effective for detecting volatile nitrosamines such as NDMA, NDEA, NDIPA, and NDBA. However, biologic drug products present unique analytical challenges because of their high protein content, elevated moisture levels, and complex formulation matrices. Method parameters such as extraction temperature, equilibration time, and sample preparation procedures must therefore be carefully optimized for biological formulations. Additionally, non-volatile nitrosamines generally cannot be analyzed using headspace GC-MS/MS and instead require LC-MS/MS-based analytical methods.
Antibody-drug conjugates require a dual risk assessment strategy because they contain both biologic and small-molecule components. The monoclonal antibody portion is evaluated using biologic-specific risk assessment principles, while the linker and cytotoxic payload components are fully subject to ICH M7(R2) requirements applicable to chemically synthesized substances. Regulatory authorities expect manufacturers to conduct independent and thoroughly documented assessments for each portion of the ADC structure. This combined approach ensures that all potential nitrosamine risks are properly addressed.
There is currently no explicit global regulatory mandate requiring nitrosamine assessments for cell and gene therapy products. Nevertheless, these advanced therapies frequently involve complex media systems, viral vectors, growth supplements, and manufacturing materials that may contain amine-related risk factors similar to those found in conventional biologics manufacturing. Viral vector production platforms such as AAV and lentiviral systems may therefore present potential nitrosamine formation concerns. Conducting a scientific risk assessment is widely considered a prudent and responsible quality practice.
The limit of quantitation (LOQ) for nitrosamine testing should generally be established at or below 10% of the applicable acceptable intake limit. For example, if the acceptable intake for NDMA is 18 ng/day, a once-daily 1 mL injectable biologic would ideally require an LOQ of 1.8 ng/mL or lower. Achieving this level of sensitivity in protein-rich biological matrices can be technically challenging. Robust method development, matrix-matched calibration, and stable isotope-labeled internal standards are typically necessary to achieve reliable quantification.
If nitrosamines are identified above established acceptable intake limits following product approval, manufacturers are generally expected to notify the appropriate regulatory authorities promptly. This is typically followed by a detailed root cause investigation, corrective and preventive action (CAPA) implementation, and a comprehensive risk assessment evaluating potential patient impact. Additional confirmatory testing and process reviews are often required to determine the source of contamination. Depending on the severity of the finding, health authorities may also require market actions, including recalls or temporary distribution restrictions.
Reference:
- ICH M7(R2) — Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. International Council for Harmonisation, 2023. https://www.ich.org/page/multidisciplinary-guidelines
- U.S. FDA. Control of Nitrosamine Impurities in Human Drugs: Guidance for Industry. September 2021 (Updated February 2023). https://www.fda.gov/media/141720/download
- European Medicines Agency. Guidance on Nitrosamine Impurities in Medicinal Products. EMA/CHMP/428592/2019 Rev.1, 2023. https://www.ema.europa.eu
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2023). Q5A(R2): Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. https://database.ich.org/sites/default/files/ICH_Q5A%28R2%29_Guideline_2023_1101.pdf
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2019). Q12: Technical and regulatory considerations for pharmaceutical product lifecycle management. https://database.ich.org/sites/default/files/Q12_Guideline_Step4_2019_1119.pdf
- European Medicines Agency. (2020). Nitrosamines EMEA-H-A5(3)-1490: Questions and answers for marketing authorisation holders/applicants on the CHMP opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products (EMA/409815/2020 Rev. 23). https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/nitrosamines-emea-h-a53-1490-questions-answers-marketing-authorisation-holders-applicants-chmp-opinion-article-53-regulation-ec-no-726-2004-referral-nitrosamine-impurities-human-medicinal-products_en.pdf
Get In Touch With Us
About The Author
